Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $22.71 USD
Change Today -0.57 / -2.45%
Volume 340.9K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Open
$23.23
Previous Close
$23.28
Day High
$23.47
Day Low
$22.54
52 Week High
08/14/14 - $40.98
52 Week Low
05/1/15 - $15.51
Market Cap
935.8M
Average Volume 10 Days
1.3M
EPS TTM
$-3.17
Shares Outstanding
41.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase I/II clinical trial of EPZ-6438, an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and advanced solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors; and two Phase 1 clinical trials of EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with genetic alterations of the MLL gene. It has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic development collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

86 Employees
Last Reported Date: 03/12/15
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $652.8K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $531.7K
Chief Development Officer
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.

epizyme inc (EPZM) Key Developments

Epizyme Announces Additional Positive Data from Ongoing Phase 1 Study of Tazemetostat (EPZ-6438)

Epizyme, Inc. reported results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class EZH2 inhibitor, showing meaningful clinical activity when used as an oral monotherapy in patients with advanced B-cell non-Hodgkin lymphomas (NHL) and solid tumors. In NHL, treatment with tazemetostat continues to demonstrate an encouraging profile with nine of 15 evaluable NHL patients achieving an objective response, including a partial response in the first treated patient with an EZH2 tumor mutation. The data, which include patients from the dose escalation and dose expansion cohorts of the phase 1 study, as well as a food effects sub-study, the following clinical data were observed: Nine of 15 evaluable NHL patients have achieved an objective response, including two patients with an ongoing complete response (CR). Five of nine evaluable diffuse large B-cell lymphoma (DLBCL) patients achieved an objective response. One patient with a CR remains on study at 18 months of treatment. Three of five evaluable patients with follicular lymphoma achieved an objective response. One patient with a CR remains on study at 13 months, and one patient with a PR remains on study at 13 months. One patient with a marginal zone lymphoma achieved a partial response and continues on study at 11 months. All treatment responses were observed between two and 10 months on therapy. One of 14 patients evaluated for EZH2 status possesses a specific EZH2 tumor mutation (Y646H). This patient, who had relapsed or been refractory to six previous treatment regimens, achieved a partial response after 16 weeks of therapy and remains on study. The majority of adverse events were grade 1 or grade 2 within the evaluable for safety population of 45 patients with NHL and solid tumors. The most common adverse events regardless of attribution were asthenia, anorexia, anemia, dyspnea and nausea. Five grade 3 or greater treatment-related adverse events were observed including one each of: grade 3 anorexia, grade 3 hypertension, grade 3 transaminase elevation, grade 4 thrombocytopenia, and grade 4 neutropenia. The NHL patients enrolled on study were heavily pre-treated, with 85% of patients having received three or more prior therapies and 37% of patients having received more than five or more prior therapies. 37% of patients were refractory to their last prior regimen and 26% of patients had received a prior autologous hematopoietic stem cell transplant. Drug pharmacokinetics showed rapid absorption with a mean terminal half-life of three to five hours. Cmax and AUC1-12hr were dose proportional at steady-state throughout the dosing range. Steady-state Ctrough levels were reached by day 15. The company plans to report a further update from the phase 1 trial by the end of 2015.

Epizyme, Inc. - Special Call

To review the tazemetostat data presented at International Conference on Malignant Lymphoma (ICML)

Epizyme Seeks Acquisitions

Epizyme, Inc. (NasdaqGS:EPZM) intends to use the net proceeds from the sale of any securities offered under this prospectus to fund clinical development of our product candidates, to fund preclinical development and research to advance our pipeline and expand our product platform and for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the acquisition of companies or businesses, repayment and refinancing of debt, if any, working capital and capital expenditures.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $22.71 USD -0.57

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies
 

Industry Analysis

EPZM

Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.5x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit www.epizyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.